The Karnataka government has launched the 'Kusuma Sanjeevini' scheme, targeting haemophilia patients. It aims to prevent bleeding episodes rather than treat them, utilizing modern preventive therapy.

Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around ...

Novo Nordisk is leaving no stone unturned in its bid to maintain its leading position in weight-loss therapies, planning for the future with a wide-ranging, $2.1 billion deal with drug delivery ...

Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address ...

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, ...

But it's good news for Eli Lilly, too.

Using proprietary copolymer technology, TEV-’749 allows for a controlled steady release of olanzapine, a second generation antipsychotic.

K'taka launches ‘Kusuma Sanjeevini’ scheme to provide free preventive care for haemophilia patients ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address ...